Zhang L, Zhang X, Wu P, et al. BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis[J]. Inflamm Res, 2008, 57(4): 157-162. [2]张力, 万敬员, 叶笃筠, 等. 脂氧素受体激动剂BML-111减轻佐剂诱导的关节炎[J]. 中国药理学通报, 2009, 25(3):？ 304-307. [3]Marrelli A, Cipriani P, Liakouli V, et al. Angiogenesis in rheumatoid arthritis:？ a disease specific process or a common response to chronic inflammation?[J]. Autoimmun Rev, 2011, 10(10): 595-598. [4]Azizi G, Boghozian R, Mirshafiey A. The potential role of angiogenic factors in rheumatoid arthritis[J]. Int J Rheum Dis, 2014, 17(4): 369-383. [5]Wang D, Hu S, Zhu J, et al. Angiotensin II type 2 receptor correlates with therapeutic effects of losartan in rats with adjuvant-induced arthritis [J]. J Cell Mol Med, 2013, 17(12):？ 1577-1587. [6]Serhan C N. Pro-resolving lipid mediators are leads for resolution physiology [J]. Nature, 2014, 510(7503):？ 92-101. [7]Romano M, Cianci E, Simiele F, et al. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation[J]. Eur J Pharmacol, 2015, 760: 49-63. [8]Zhang L, Wu P, Jin S W, et al. Lipoxin A4 negatively regulates lipopolysaccharide-induced differentiation of RAW264.7 murine macrophages into dendritic-like cells [J]. Chin Med J (Engl), 2007, 120(11): 981-987. [9]张力, 吴萍, 万敬员, 等. 脂氧素对Jurkat T细胞增殖和白细胞介素-2/白细胞介素-2受体表达的影响[J]. 中国病理生理杂志, 2008, 24(1): 162-164. [10]Grochot-Przeczek A, Dulak J, Jozkowicz A. Therapeutic angiogenesis for revascularization in peripheral artery disease[J]. Gene, 2013, 525(2):？ 220-228. [11]Shiozawa S, Tsumiyama K, Yoshida K, et al. Pathogenesis of joint destruction in rheumatoid arthritis[J]. Arch Immunol Ther Exp (Warsz), 2011, 59(2):？ 89-95. [12]Baker N, O'Meara S J, Scannell M, et al. Lipoxin A4:？ anti-inflammatory and anti-angiogenic impact on endothelial cells[J]. J Immunol, 2009, 182(6):？ 3819-3826. [13]Leedom A J, Sullivan A B, Dong B, et al. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury[J]. Am J Pathol, 2010, 176(1): 74-84. [14]Choe J Y, Lee S J, Park S H, et al. Tacrolimus (FK506) inhibits interleukin-1β-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes[J]. Joint Bone Spine, 2012, 79(2):？ 137-143. [15]Wang Y P, Wu Y, Li L Y, et al. Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-κB and MAPKs in BV-2 microglial cells[J]. J Neuroinflammation, 2011, 8: 95. [16]Wu S H, Liao P Y, Dong L, et al. Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide[J]. Inflamm Res, 2008, 57(9):？ 430-437. [17]Lv W, Lv C, Yu S, et al. Lipoxin A4 attenuation of endothelial inflammation response mimicking pancreatitis-induced lung injury[J]. Exp Biol Med (Maywood), 2013 238(12): 1388-1395. [18]Konisti S, Kiriakidis S, Paleolog E M. Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis[J]. Nat Rev Rheumatol, 2012, 8(3):？ 153-162. [19]Lokmic Z, Musyoka J, Hewitson T D, et al. Hypoxia and hypoxia signaling in tissue repair and fibrosis[J]. Int Rev Cell Mol Biol, 2012, 296: 139-185. [20]Liu S, Wu P, Ye D, et al. Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells[J]. Pharmacology, 2009, 84(1): 17-23. [21]Lee Y A, Choi H M, Lee S H, et al. Hypoxia differentially affects IL-1β-stimulated MMP-1 and MMP-13 expression of fibroblast-like synoviocytes in an HIF-1α-dependent manner[J]. Rheumatology, 2012, 51(3):？ 443-450.
